Adolor Corp.

Senior Vice President, Finance and Chief Financial Officer; Mr. Webster has over 20 years of Healthcare Industry related experience, most recently serving as Managing Director, Healthcare Investment Banking at Broadpoint Capital (formerly First Albany Capital). Prior to Broadpoint Capital, Mr. Webster was co-founder, President and CEO of Neuronyx, Inc., a privately-held biotechnology company. Mr. Webster also spent over 13 years at PaineWebber Incorporated, including as Director, Investment Banking Division, Health Care Group. Mr. Webster earned his MBA in Finance from The Wharton School and his AB in Economics cum laude from Dartmouth College. Mr. Webster currently sits on the Board of Directors of the Pennsylvania BIO Association.

Vice President, Finance and Chief Operating Officer; previously Corporate Controller of Vicuron Pharmaceuticals, Inc., an international biopharmaceutical company that was acquired by Pfizer, Inc. in 2005, where Mr. Hess was respon...

Senior Vice President, General Counsel and Secretary; previously Senior Vice President, General Counsel, and Secretary at Cell Pathways, an emerging pharmaceutical company. Prior to Cell Pathways, Ms. Manning was Executive Vic...

Vice President, Quality Assurance; previously Senior Director, Quality Assurance at Adolor Corporation. Prior to joining Adolor, Mr. Stephon held several successive director positions with Elan Pharmaceuticals, a drug delivery...

Vice President Human Resources; previously Senior Director Human Resources at Adolor Corporation. Prior to that, Ms. Kerton was Executive Vice President for global human resources and facilities with Omnicare Clinical Research,...

Mr. Wilson was previously Vice President, Sales and Marketing of Discovery Labs, where he developed their U.S. commercial operations. Prior to that, Mr. Wilson held Sales & Marketing positions of incr...

Vice President, Business Development; previously Vice President, Business Development of Codexis, Inc., a privately held biosciences company, where Mr. Taylor built a business development team with strategic hires in Europe, and t...

Vice President of Regulatory Affairs; previously Vice President of Regulatory Affairs with IBAH, Inc., a subsidiary of Omnicare, Inc. a multinational clinical research organization (CRO). Prior to that, Ms. Young (formerly Ms. Har...

Vice President, Discovery; previously Senior Director, Pharmacology at Purdue Pharma, LP. Prior to joining Purdue, Dr. Woodward held successive positions with CoCensys, Inc., initially as an Associate Director, In Vivo Pharmac...

Vice President, Marketing; previously Senior Director of Marketing at Schering-Plough, where he led the re-positioning and messaging of PegIntron globally. Prior to that, Mr. Megaffin developed the platform for key commercial...

Armando Anido has served as one of our directors since July 2006 and Chief Executive Officer and President since July 2006. Since August 2003, Mr. Anido has served as a director of Adolor Corporation and currently serves as Chairman of the Governance and Nominating Committee. Mr. Anido has over 25 years of biopharmaceutical experience. Prior to Auxilium, he was the Executive Vice President, Sales and Marketing for MedImmune, Inc., a biotechnology company focused on developing and marketing products in the therapeutic areas of cancer, infectious disease and immune regulation, where he was responsible for worldwide commercialization of their portfolio. He also served on MedImmune s Executive Committee and Product Development Committee. Prior to joining MedImmune in 1999, from 1995 to 1999, Mr. Anido was with GlaxoWellcome, Inc. where he served as Vice President, Central Nervous System Marketing after joining the company as Director, HIV Marketing. Mr. Anido was employed by Lederle Labs from 1989 to 1995 in various commercial roles, culminating as Vice President, Anti-infectives. Mr. Anido received his B.S. in Pharmacy and his M.B.A. in Marketing and Finance from West Virginia University.

Dr. Gemayel was appointed President and Chief Executive Officer and to the Company’s Board of Directors, effective June 2, 2008. Dr. Gemayel joins Altus Pharmaceuticals from Genzyme Corporation where he was Executive Vice President and a corporate officer. Dr. Gemayel joined Genzyme in 2003. He was responsible for the company’s therapeutics, transplant, renal and biosurgery businesses. Before he joined Genzyme, Dr. Gemayel worked for the health care company Hoffman-LaRoche for 16 years. There he served as Vice President of the U.S. Specialty Care Business with responsibilities for oncology, transplantation, hepatitis, HIV and dermatology. He also was the general manager of Hoffman-LaRoche, Portugal. Dr. Gemayel completed his doctorate in pharmacy at St. Joseph University in Beirut and earned a Ph.D. in pharmacology at Paris-Sud University.

Dr. Goddard has served as the chairman of our board of directors since August 2003 and was appointed our chief executive officer in April 2005. From March 2000 and August 2005, Dr. Goddard served as chairman and part-time executive of several companies including A.P. Pharma, Inc., a pharmaceutical company, and XenoPort, Inc., a biopharmaceutical company. From October 1998 until March 2000, he was chief executive officer of Elan Pharmaceuticals, Inc., the largest division of Elan Corporation plc, a biotechnology company. He was chief executive officer of Neurex Corporation, a biotechnology company, from February 1991 until October 1998 when the company was acquired by Elan Corporation plc. Prior to 1991, Dr. Goddard held various senior management positions at SmithKline Beecham plc, a pharmaceutical company, including senior vice president strategic marketing and senior vice president Far East region. He obtained his doctorate degree from St. Mary's Hospital, London, in the area of etiology and pathophysiology of colon cancer. Dr. Goddard remains on the board of directors of A.P. Pharma, Inc., Adolor Corporation, a biopharmaceutical company, and Onyx Pharmaceuticals, Inc., a biopharmaceutical company.